Vaginal squamous cell carcinoma

Summary

Vaginal squamous cell carcinoma (MONDO:0006490) is a cancer and 3 clinical trials. Top therapeutic interventions include cisplatin and triapine. A subtype of vaginal squamous tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vaginal squamous cell carcinoma
Mondo ID	MONDO:0006490
EFO	EFO:1000620
NCIT	C180915, C7736
SNOMED CT	105121000119102
UMLS	C0238518
MedGen	66775
GARD	0024432
Anatomy (UBERON)	UBERON:0000996
Is cancer (heuristic)	yes

Also known as: carcinoma of vagina squamous cell · epidermoid carcinoma of the vagina · epidermoid carcinoma of vagina · epidermoid cell carcinoma of the vagina · epidermoid cell carcinoma of vagina · squamous cell carcinoma of the vagina · squamous cell carcinoma of the vulva/vagina · squamous cell carcinoma of vagina · vagina epidermoid carcinoma · vagina epidermoid cell carcinoma · vagina squamous cell carcinoma · vaginal epidermoid carcinoma · vaginal epidermoid cell carcinoma · vaginal squamous cell cancer · vaginal squamous cell cancer, NOS · vaginal squamous cell carcinoma

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › vaginal squamous tumor › vaginal squamous cell carcinoma

Related subtypes (1): vaginal squamous papilloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02466971	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT02595879	PHASE1	ACTIVE_NOT_RECRUITING	Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
NCT07217171	PHASE1	RECRUITING	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	2
TRIAPINE	3	2